These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25463410)

  • 1. Breast magnetic resonance imaging performance: safety, techniques, and updates on diffusion-weighted imaging and magnetic resonance spectroscopy.
    Melsaether A; Gudi A
    Top Magn Reson Imaging; 2014 Dec; 23(6):373-84. PubMed ID: 25463410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 3. NSF: still relevant.
    Thomsen HS
    J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
    [No Abstract]   [Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: chemical structure and stability of gadolinium chelates.
    Idée JM; Port M; Corot C
    Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
    Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
    [No Abstract]   [Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P
    J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
    [No Abstract]   [Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A; Kirchin MA; Pirovano G
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract]   [Full Text] [Related]  

  • 10. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.
    Juluru K; Vogel-Claussen J; Macura KJ; Kamel IR; Steever A; Bluemke DA
    Radiographics; 2009; 29(1):9-22. PubMed ID: 19019996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 12. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 13. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 14. Contrast-enhanced magnetic resonance angiography of the peripheral arteries: technique, tips, pitfalls and problems.
    Welman CJ; Harrison C; Low RS
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):125-40. PubMed ID: 23551769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium-induced NSF claim resolved in favor of plaintiff.
    Ball JB; Samaritan G
    J Med Assoc Ga; 2012; 101(3):32-3. PubMed ID: 23198628
    [No Abstract]   [Full Text] [Related]  

  • 16. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium- or iodine-based contrast media: which choice?
    Thomsen HS
    Acta Radiol; 2014 Sep; 55(7):771-5. PubMed ID: 25138436
    [No Abstract]   [Full Text] [Related]  

  • 18. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
    Jain R; Levine M
    Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
    [No Abstract]   [Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
    Martin DR
    Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium and nephrogenic systemic fibrosis.
    Runge VM
    AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.